Robin J. Davenport
About Robin J. Davenport
Independent director of Standex International since 2021; age 63; currently serves as Audit Committee Chair and member of the Compensation Committee. Prior roles include senior finance and M&A leadership at Parker Hannifin and CNH Capital, with focus areas in M&A, capital allocation, corporate strategy, and disclosure oversight; she served on Parker Hannifin’s Disclosure Committee from 2014–2022. The Board classifies her as independent under NYSE rules; all Audit and Compensation Committee members meet enhanced independence standards. Term: Class I director, expiring 2027.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Parker Hannifin Corporation | Vice President, Corporate Finance | 2014–2022 | Member, Disclosure Committee (2014–2022); finance leadership across M&A, capital allocation, strategy |
| Parker Hannifin Corporation | Vice President, Business Planning & Development | 2004–2014 | Led business planning and development initiatives |
| CNH Capital | Vice President, Business Planning & Development | 1996–2003 | Strategic and finance leadership in capital operations |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Public company boards | None | N/A | No current or prior public company directorships disclosed |
| Parker Hannifin (external to Standex) | Disclosure Committee member | 2014–2022 | Oversight of disclosure controls and procedures |
Board Governance
| Item | Details |
|---|---|
| Board/Committee meetings | Board held 7 meetings in FY2025; committees held 17; each director attended at least 75% of Board and committee meetings; all directors attended 2024 annual meeting |
| Committee assignments | Audit Committee Chair; Compensation Committee member |
| Committee independence and expertise | All Audit Committee members are independent and designated “audit committee financial experts”; Compensation Committee members are independent |
| FY2025 committee composition | Audit: Robin J. Davenport (Chair), Thomas E. Chorman, Charles H. Cannon Jr., Thomas J. Hansen; meetings held: 4. Compensation: Michael A. Hickey (Chair), B. Joanne Edwards, Robin J. Davenport, Jeffrey S. Edwards; meetings held: 5 |
| Lead Independent Director | Michael A. Hickey; responsibilities include presiding executive sessions, CEO evaluation, liaison role, and shareholder consultation |
| Independence status | Board determined all directors other than CEO David Dunbar are independent (July 24, 2025) |
Fixed Compensation
| Period | Cash Retainer & Committee Fees ($) | Notes |
|---|---|---|
| FY2025 | 80,000 | Includes annual cash retainer and chair/member fees, net of any MSPP deferrals |
| FY2024 | 97,500 | Audit Chair ($20,000) + Compensation member ($7,500) + $70,000 base retainer aligns to total; no meeting fees |
Program structure and guidelines:
- FY2025 non-employee director elements: annual cash retainer $70,000; Audit Chair $20,000; Compensation member $7,500; annual equity stock grant $130,000; no meeting fees or perquisites. Directors must hold at least 5x annual cash retainer; all directors were in compliance as of June 30, 2025. Anti-hedging and anti-pledging policy prohibits short-term trading, derivatives, margin accounts, and pledging.
Performance Compensation
| Period | Stock Awards ($) | Grant Details | Vesting | Unvested Shares (#) |
|---|---|---|---|---|
| FY2025 | 156,335 | Annual equity stock grant on Oct 24, 2024 valued at $177.55/share; MSPP RSUs certified Aug 12, 2025 and granted Aug 22, 2025 valued at $120.86/share (25% discount) | Restricted stock vests 3 years; dividend equivalents paid upon vesting; acceleration upon retirement or change-in-control | 2,935 |
| FY2024 | 130,000 | Annual equity stock grant on Oct 24, 2023 valued at $143.04/share; MSPP RSUs certified Aug 20, 2024 and granted Aug 23, 2024 valued at $120.86/share (25% discount) | Restricted stock vests 3 years; dividend equivalents paid upon vesting; acceleration upon retirement or change-in-control | 3,321 |
Notes:
- All other director compensation in FY2025 comprised dividend equivalents ($3,756).
- Standex emphasizes equity and long-term focus for directors; no meeting fees or retirement plan benefits.
Other Directorships & Interlocks
- Other public company boards: none disclosed for Davenport.
- Compensation Committee interlocks: none; no cross-board relationships involving Standex executives.
- Shared directorships with customers/suppliers/competitors: none disclosed.
Expertise & Qualifications
- Financial and global manufacturing expertise; audit committee financial expert designation at committee level; deep background in M&A, capital allocation, corporate strategy; disclosure controls experience.
- Sector experience: diversified manufacturing and industrials via Parker Hannifin and CNH Capital.
Equity Ownership
| Holder | Shares Beneficially Owned | % Outstanding | Notes |
|---|---|---|---|
| Robin J. Davenport | 4,053 | <1% | Beneficial ownership includes certain share units convertible within 60 days per footnote 1; directors in compliance with 5x retainer ownership guideline as of 6/30/2025 |
Policies and compliance:
- Anti-hedging and anti-pledging: prohibits derivatives, margin accounts, and pledging; no prohibited transactions by directors in FY2025 or prior periods.
- Section 16(a) filings: all directors timely filed in FY2025.
Governance Assessment
- Strengths: Independent director with deep finance/M&A background; Audit Chair with committee designated “financial expert” credentials; consistent attendance standards; equity-heavy director pay and robust ownership requirements; strong anti-hedging/anti-pledging and related party policies; no interlocks or conflicts disclosed.
- Alignment signals: Three-year vesting equity grants; dividend equivalents paid only upon vesting; all directors in compliance with 5x retainer ownership guideline.
- RED FLAGS: None disclosed—no related party transactions since July 1, 2024; no hedging/pledging; no director perquisites; no meeting fees that could incentivize excessive meetings.
- Watch items: FY2025 cash fees lower than FY2024 (likely MSPP deferral); continue to monitor director equity deferrals and committee workload given Audit Chair responsibilities amidst cyber and ESG oversight expansions.